Friday, December 19, 2014
FAIRFIELD-SUISUN, CALIFORNIA
99 CENTS

Merck to pay $3.85B for hepatitis C drug developer

Merck

FILE - This Thursday, Feb. 28, 2013 file photo shows a patch with the Merck logo on a scientist's lab coat in West Point, Pa. Merck on Monday, June 9, 2014 announced it will spend nearly $4 billion for Idenix Pharmaceuticals with a per-share bid that more than triples the hepatitis C drug developer’s latest closing price. (AP Photo/Matt Rourke, File)

By
June 10, 2014 |

TRENTON, N.J. — Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck’s experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.

The price for the deal announced Monday — a per-share bid more than triple Friday’s closing price for Cambridge, Massachusetts-based Idenix — seems high. However, the latest hepatitis C medicines command very high prices, the number of patients keeps rising and Merck was bidding against rivals.

Hepatitis C has become one of the hottest categories in drug research as companies race to develop a combination therapy without injections and debilitating side effects. Some have had their promising candidates fail after extensive testing, due to dangerous side effects, but Gilead Sciences Inc. is already raking in billions of dollars from its groundbreaking new drug, Sovaldi.

Merck, based in Whitehouse Station, New Jersey, said it will spend $24.50 in cash for each Idenix share. Idenix closed at $7.23 on Friday, then more than tripled at Monday’s opening bell.

The boards of both companies have approved the deal, which should close in the third quarter.

“Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in (certain) technologies,” Merck’s research head, Dr. Roger Perlmutter, said in a statement.

Three Idenix experimental drugs have reached human testing and one, samatasvir, is in mid-stage testing. It’s in a new drug class called NS5A inhibitors, which disrupt various stages of the virus life cycle. Two other drugs, known as IDX21437 and IDX21459, are in a class called nucleotide prodrugs, which stop the virus from producing genetic material needed to copy itself.

Merck has been testing two drugs together, MK-5172 and MK-8742, that the Food and Drug Administration has deemed a breakthrough therapy. Merck will soon start late-stage testing of the two drugs together and presumably will study them in combinations with the Idenix drugs.

About 4.4 million Americans and an estimated 170 million people worldwide have chronic hepatitis C, the leading cause of liver cancer and, in wealthy countries, the top reason for liver transplants. In the U.S., it kills more than 16,000 people a year.

While most people infected don’t know it because there are no obvious symptoms, a growing number have been identified and started treatment in the last few years as more effective medicines have been approved. That number is expected to grow as the U.S. population ages and patients infected decades ago through intravenous drug use, or from blood transfusions before the early 1990s, are diagnosed.

Merck has been a major player in hepatitis C since acquiring Schering-Plough in 2009. Back then, treatment was limited to twice-a-day pills called ribavirin and self-injections of a long-acting, synthetic form of immune system protein interferon. Treatment often lasted 48 weeks, only about 40 percent of patients were cured, and flu-like symptoms and other side effects of the interferon kept many patients from completing treatment.

In 2011, the FDA approved two drugs in a class called protease inhibitors, Merck’s Victrelis and Incivek from Vertex Pharmaceuticals. Those are taken with ribavirin and interferon, work by blocking an enzyme needed for copying the virus, and boost the cure rate to about 75 percent. But they require patients to take a dozen pills a day, and still endure flu-like side effects.

Last December, the FDA approved Gilead’s once-a-day pill Sovaldi, which cures 80 percent to 90 percent of patients, without the interferon injections and side effects.

Physicians quickly embraced it, and Sovaldi racked up more than $2 billion in sales in its first full quarter on sale, considered the best new drug launch in history. That’s mainly because of Sovaldi’s high price, about $1,000 per pill, or $84,000 for a 12-week treatment course, which continues to draw criticism from patients, insurers and government.

Sovaldi appears poised to dominate the hepatitis C market, greatly outselling Johnson & Johnson’s Olysio, approved about the same time. But there’s plenty of room for Merck and others because Sovaldi can’t be taken by some patients with multiple illnesses or certain hepatitis C subtypes.

In afternoon trading, Idenix shares climbed $16.76 to $23.99. Merck shares slipped 5 cents to $57.80.

Shares of another hepatitis C drug developer, Achillion Pharmaceuticals Inc., now seen as a potential takeover target, climbed 58 percent to $4.55.

 

The Associated Press

The Associated Press

LEAVE A COMMENT

Discussion | No comments

The Daily Republic does not necessarily condone the comments here, nor does it review every post. Read our full policy

  • Recent Articles

  • Enter your email address to subscribe and receive notifications of new posts by email.

  • .

    Solano News

     
    Sondheim’s ‘Woods’ holiday showcase for Missouri Street Theatre

    By Amy Maginnis-Honey | From Page: B1 | Gallery

    Groundbreakings, ribbon-cuttings play role in civic life

    By Barry Eberling | From Page: A1, 1 Comment | Gallery

     
    Frankye Kelly ready to spread holiday cheer

    By Amy Maginnis-Honey | From Page: B1

     
    Celebrate the magic of Christmas

    By Tony Wade | From Page: A2, 2 Comments

     
    Santas have busy week at schools

    By Susan Hiland | From Page: A3, 1 Comment

     
    Safe streets task force work nets 3

    By Ryan McCarthy | From Page: A3, 1 Comment

     
    Solano College approves officers, meeting schedule

    By Susan Winlow | From Page: A4

    Longtime Suisun harbor master to retire

    By Ian Thompson | From Page: A4

     
     
     
    Fairfield police log: Dec. 17, 2014

    By Susan Hiland | From Page: A12

     
    Suisun City police log: Dec. 17, 2014

    By Susan Hiland | From Page: A12, 1 Comment

    Police arrest 2nd suspect in Fairfield credit union robbery

    By Ryan McCarthy | From Page: A12 | Gallery

     
    .

    US / World

    Hope and some fear in Cuba amid thaw with US

    By The Associated Press | From Page: A1

     
    Next steps on Cuba: Normalizing could take awhile

    By The Associated Press | From Page: A1

    Sony hacking fallout puts all companies on alert

    By The Associated Press | From Page: A1

     
    Sony film took aim at North Korea’s biggest taboo

    By The Associated Press | From Page: A1, 3 Comments

    Timeline of the Sony Pictures Entertainment hack

    By The Associated Press | From Page: A1

     
    Digital dilemma: How will US respond to Sony hack?

    By The Associated Press | From Page: A1

     
    Spy’s parents search for son after Cuba-US deal

    By The Associated Press | From Page: A1

    California’s top utility regulator defends record

    By The Associated Press | From Page: A5

     
    ‘Pretty horrible’ scene; car slams into crowd

    By The Associated Press | From Page: A5

     
    Police: Drunk man shot while entering wrong house

    By The Associated Press | From Page: A5, 4 Comments

     
    Local emergencies in Northern California counties after rain

    By The Associated Press | From Page: A5

    Tsarnaev appears in court for 1st time since 2013

    By The Associated Press | From Page: A6

     
    President signs legislation ending Nazi benefit checks

    By The Associated Press | From Page: A7

    2 states challenge Colorado marijuana legalization

    By The Associated Press | From Page: A8, 3 Comments

     
    ‘Prison Houdini’ set to make his 1st legal escape

    By The Associated Press | From Page: A8

    Top Islamic militants killed; more US troops going to Iraq

    By The Associated Press | From Page: A8

     
    Feds sue NYC over Rikers Island jail violence

    By The Associated Press | From Page: A8

    Russian sailors leaving France without warship

    By The Associated Press | From Page: A9, 1 Comment

     
    Putin: West wants to defang, declaw Russian bear

    By The Associated Press | From Page: A10

    Suspected Islamic extremists kidnap 185 in Nigeria

    By The Associated Press | From Page: A13, 2 Comments

     
    European court rules obesity can be a disability

    By The Associated Press | From Page: A13

    .

    Opinion

    News of the day strikes a chord

    By Bud Stevenson | From Page: A11, 10 Comments

     
     
    Another look at school bonds

    By George Guynn Jr. | From Page: A11, 2 Comments

    Editorial Cartoon: Dec. 19, 2014

    By Daily Republic Syndicated Content | From Page: A11

     
    .

    Living

    Today in History: Dec. 19, 2014

    By The Associated Press | From Page: A2, 1 Comment

     
    Community Calendar: Dec. 19, 2014

    By Susan Hiland | From Page: A2

    Horoscopes: Dec. 19, 2014

    By Holiday Mathis | From Page: D8

     
    Should I use Child Protective Services threat to get back rent?

    By Kathy Mitchell and Marcy Sugar | From Page: D8

    .

    Entertainment

    Week in preview Dec. 19-25, 2014

    By Amy Maginnis-Honey | From Page: B1

     
    Sweet ‘Night at the Museum’ bids farewell to Robin Williams

    By The Associated Press | From Page: B2

    Review: ‘The Hobbit’ wraps with a Middle Earth melee

    By Jake Coyle | From Page: B2 | Gallery

     
    Craig Ferguson to end 10 years as host of ‘Late Late Show’

    By The Associated Press | From Page: B3

    Eric Idle brings ‘Not the Messiah’ to Carnegie Hall

    By The Associated Press | From Page: B3

     
    Entertainment calendar Dec. 19, 2014

    By Susan Hiland | From Page: B4

    .

    Sports

     
    Warriors beat Thunder 114-109 after Durant injury

    By The Associated Press | From Page: B7

    A’s acquire lefty De La Rosa from Arizona for cash

    By The Associated Press | From Page: B7

     
    Raiders defense depleted by injuries

    By The Associated Press | From Page: B7

    49ers’ Harbaugh mum on reported offer from Michigan

    By The Associated Press | From Page: B7

     
    49ers’ Aldon Smith hopes to build off tough year

    By The Associated Press | From Page: B7

    A’s trade All-Star catcher Derek Norris to Padres

    By The Associated Press | From Page: B7

     
    ‘Hands Up’ players to attend Ferguson Christmas party

    By The Associated Press | From Page: B8

    Celtics trade Rondo to Mavericks

    By The Associated Press | From Page: B8

     
    Rodriguez boys open Les Curry Tournament with victory

    By Daily Republic staff | From Page: B8

    39 bowl games and a reason to watch every one

    By The Associated Press | From Page: B8

     
    Column: Thaw in US-Cuba relations warms up MLB

    By Jim Litke | From Page: B8

    Rivera: Newton ‘probably’ will start vs. Browns

    By The Associated Press | From Page: B8

     
    Bears bench QB Jay Cutler for Clausen

    By The Associated Press | From Page: B8

    Signups for Friday, Dec. 19, 2014

    By Paul Farmer | From Page: B9

     
    This date in sports history for Friday, Dec. 19, 2014

    By The Associated Press | From Page: B11

    Sports on TV/Local sports for Friday, Dec. 19, 2014

    By Paul Farmer | From Page: B11

     
    .

    Business

    Roomiest Subaru Legacy debuts for 2015

    By Ann M. Job | From Page: C1

     
    Ford expands drivers air bag recall nationwide

    By The Associated Press | From Page: B6

    Constantly changing online prices stump shoppers

    By The Associated Press | From Page: B6

     
    Dow industrials have their best day in three years

    By The Associated Press | From Page: B6

    .

    Obituaries

    Lisa Dee McHughes

    By Nancy Green | From Page: A4

     
    Dominic C. Scolaro

    By Nancy Green | From Page: A4

    Ernest “Ernie” Moretti

    By Nancy Green | From Page: A4

     
    Travis Curt Price

    By Susan Hiland | From Page: A4, 1 Comment

    Jennie Ponce Reyes

    By Nancy Green | From Page: A4

     
    Patricia “Pat” Anne Stringfield-Pierre

    By Nancy Green | From Page: A4

    .

    Comics